Common use of Safe Harbor Statement Clause in Contracts

Safe Harbor Statement. This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the operation of the collaboration with Amgen, the efficacy, safety and intended utilization of our product candidates, including the BiTE antibodies that are the subject of the agreement with Amgen, the mode of action of BiTE antibodies, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, the initiation of a second BiTE program under the collaboration with Amgen and the future payment of upfront, milestone and royalty payments by Amgen. You are urged to consider statements that include the words "ongoing," "may," “eligible,” "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that our product candidates do not demonstrate safety and/or efficacy in pre-clinical studies or clinical trials, delays in development and testing, including the risk that Amgen will not obtain approval to market our product candidates and the risks associated with reliance on collaboration partners such as Amgen and outside financing to meet capital requirements. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2010, and Micromet’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2011, filed with the SEC on May 10, 2011 as well as other filings by the Company with the SEC. *** Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Contact: ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ Director, Corporate Communications Micromet, Inc. ▇▇▇-▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇.▇▇▇▇▇▇@▇▇▇▇▇▇▇▇.▇▇▇ *** Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Safe Harbor Statement. This press release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results are made pursuant to be materially different from historical results or from any future results expressed or implied by such forward-looking statementsthe safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These Such forward-looking statements include statements regarding the operation of the collaboration with Amgen, the efficacy, safety status and intended utilization prospects of our commercialization of FOLOTYN for the treatment of patients with relapsed or refractory PTCL; our Marketing Authorisation Application (MAA) for FOLOTYN in Europe; our future product candidatesdevelopment and regulatory strategies, including the BiTE antibodies that are the subject of the agreement with Amgen, the mode of action of BiTE antibodies, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, the initiation of a second BiTE program under the collaboration with Amgen and the future payment of upfront, milestone and royalty payments by Amgen. You are urged intent to consider statements that include the words "ongoing," "may," “eligible,” "will," "believes," "potential," "expects," "plans," "anticipates," "intends," develop or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that seek regulatory approval for FOLOTYN in additional indications; our product candidates do not demonstrate safety and/or efficacy in pre-clinical studies or clinical trials, delays in development and testing, including the risk that Amgen will not obtain approval to market our product candidates and the risks associated with reliance on collaboration partners such as Amgen and outside financing to meet capital requirements. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2010, and Micromet’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2011, filed with the SEC on May 10, 2011 as well as other filings by the Company with the SEC. **[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and is filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Contactstrategic collaboration with Mundipharma, including the parties intent to co-develop FOLOTYN in additional indications and Mundipharma's potential commercialization of FOLOTYN outside the United States and Canada; and other statements that are other than statements of historical facts. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "continue," and other similar terminology or the negative of these terms, but their absence does not mean that a particular statement is not forward-looking. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forward-looking statements. Important factors that may cause actual results to differ materially include, but are not limited to, the risks and uncertainties associated with the commercialization of FOLOTYN; the ability to expand the approved indications for FOLOTYN; that the design of and data collected from the Company's pivotal PROPEL trial may not be adequate to demonstrate the safety and efficacy of FOLOTYN for the treatment of patients with relapsed or refractory PTCL, or otherwise be sufficient to support EMA approval; and the establishment, implementation and execution of the Company's strategic collaboration with Mundipharma, including the parties future product development and commercialization strategies. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011, and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law. Note: ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ Director, Corporate Communications MicrometThe Allos logo and FOLOTYN name are registered trademarks of Allos Therapeutics, Inc. ▇▇▇-▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇.▇▇▇▇▇▇@▇▇▇▇▇▇▇▇.▇▇▇ **Sources: Allos Therapeutics, Inc. and Mundipharma International Corporation Limited [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and is filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Editor's Note: This press release is also available under the Media section of Allos Therapeutics' website at ▇▇▇.▇▇▇▇▇.▇▇▇ and at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇.▇▇.▇▇ References:

Safe Harbor Statement. This press release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding within the operation meaning of Section 27A of the collaboration with Amgen, the efficacy, safety and intended utilization Securities Act of our product candidates, including the BiTE antibodies that are the subject of the agreement with Amgen, the mode of action of BiTE antibodies, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, the initiation of a second BiTE program under the collaboration with Amgen and the future payment of upfront, milestone and royalty payments by Amgen. You are urged to consider statements that include the words "ongoing," "may," “eligible,” "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that our product candidates do not demonstrate safety and/or efficacy in pre-clinical studies or clinical trials, delays in development and testing, including the risk that Amgen will not obtain approval to market our product candidates and the risks associated with reliance on collaboration partners such as Amgen and outside financing to meet capital requirements. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K1933, as amended, for the fiscal year ended December 31, 2010, and Micromet’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2011, filed with the SEC on May 10, 2011 as well as other filings by the Company with the SEC. *** Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 Section 21E of the Securities Exchange Act of 1934, as amended, including statements about the growth and profitability of the Company. Contact: ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ Director, Corporate Communications Micromet, Inc. ▇▇▇-▇▇▇-▇▇▇▇ ▇▇▇▇▇▇▇▇.▇▇▇▇▇▇@▇▇▇▇▇▇▇▇.▇▇▇ *** Certain confidential information contained Any statements in this documentpress release that are not statements of historical fact may be considered to be forward-looking statements. Written words, marked by bracketssuch as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, has been omitted identify forward-looking statements. By their nature, forward-looking statements and filed separately forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future. There are a number of factors that could cause actual results and developments to differ materially, including, but not limited to our ability to: successfully implement our strategy to stabilize our subscriber base and grow; avoid significant subscriber declines; attract and retain members; convert members into paying subscribers and retain our paying subscribers; retain and enhance the new marketing team; develop or acquire new product offerings and successfully implement and expand those offerings; keep pace with rapid technological changes, including making the technology stack more nimble; drive use of newly-updated mobile applications; maintain the strength of our existing brands and maintain and enhance those brands; continue to depend upon the telecommunications infrastructure and our networking hardware and software infrastructure; estimate on-going general and administrative costs, and obtain financing on acceptable terms. Additional factors that could cause actual results to differ are discussed under the heading "Risk Factors" and in other sections of the Company's filings with the Securities and Exchange Commission pursuant ("SEC"), and in the Company's other current and periodic reports filed or furnished from time to Rule 24b-2 time with the SEC. All forward-looking statements in this press release are made as of the Securities Exchange Act date hereof, based on information available to the Company as of 1934the date hereof, as amendedand the Company assumes no obligation to update any forward-looking statement or provide similar metrics in future periods.